Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 4, 2015, Pages 666-672

  Bhatia, Monica ^a   Kolva, Elissa ^b   Cimini, Laura ^c   Jin, Zhezhen ^c   Satwani, Prakash ^a   Savone, Mirko ^a   George, Diane ^a   Garvin, James ^a   Paz, Mary Llenell ^c   Briamonte, Courtney ^a   Cruz Arrieta, Eduvigis ^a   Sands, Stephen ^a  

^a Department of Medicine   (United States)

^b FORDHAM UNIVERSITY   (United States)

^c Columbia University ^*  (United States)

Author keywords

Health related quality of life; Quality of life; Sickle cell disease; Stem cell transplantation

Indexed keywords

ALEMTUZUMAB; BUSULFAN; FLUDARABINE; MELPHALAN;

ACINETOBACTER INFECTION; ACUTE CHEST SYNDROME; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BETA THALASSEMIA; BLOOD GROUP ABO INCOMPATIBILITY; BONE MARROW; BRAIN HEMORRHAGE; CAREGIVER; CEREBROVASCULAR ACCIDENT; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DACTYLITIS; DIARRHEA; EVENT FREE SURVIVAL; FATALITY; FEMALE; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; GRAM NEGATIVE SEPSIS; HERPES ZOSTER; HUMAN; HYPOMAGNESEMIA; KARNOFSKY PERFORMANCE STATUS; MALE; MEDICAID; MEDICAL HISTORY; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PHYSICAL ACTIVITY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIVATE HEALTH INSURANCE; PROXY; PSYCHOLOGICAL WELLBEING ASSESSMENT; QUALITY OF LIFE; RETINOPATHY; SELF REPORT; SICKLE CELL ANEMIA; SOCIAL INTERACTION; SPLEEN DISEASE; SPLENIC SEQUESTRATION; UNRELATED DONORS; VEIN OCCLUSION; ALLOGRAFT; ANEMIA, SICKLE CELL; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ALLOGRAFTS; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; QUALITY OF LIFE;

EID: 84924278004     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.12.007     Document Type: Article

References (33)

1. Khoury R., Abboud M.R. Stem-cell transplantation in children and adults with sickle cell disease: an update. Exp Rev Hematol 2011, 4:343-351.
2. Bhatia M., Walters M.C. Hematopoietic stem cell transplantation for thalassemia and sickle cell disease: Past, present and future. Bone Marrow Transplant 2008, 41:109-117.
3. Schnog J.B., Duits A.J., Muskiet F.A., et al. Sickle cell disease: a general overview. Neth J Med 2004, 62:364-374.
4. Castro O., Gladwin M.T. Pulmonary hypertension in sickle cell disease: Mechanisms, diagnosis, and management. Hematol Oncol Clin North Am 2006, 19:881-896.
5. Chiang E.Y., Frenette P.S. Sickle cell vaso-occlusion. Hematol Oncol Clin North Am 2005, 19:771-784.
6. Dampier C., LeBeau P., Rhee S., et al. Health-related quality of life in adults with sickle cell disease (SCD): A report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol 2011, 86:203-205.
7. Walters M.C., Patience M., Leisenring W., et al. Bone marrow transplantation for sickle cell disease. NEngl J Med 1996, 335:369-376.
8. Kristovich K., Callard E. Bone marrow transplantation in primary care of the child with a chronic condition 2010, Mosby Elsevier, New York. 5th ed.
9. Casey R., Brown R., Bakeman R. Predicting adjustment in children and adolescents with sickle cell disease: a test of the risk-resistance-adaptation model. Rehab Psychol 2000, 45:155-178.
10. Kelly M.J., Pennarola B.W., Rodday A.M., et al. Health-related quality of life (HRQoL) in children with sickle cell disease and thalassemia following hematopoietic stem cell transplant (HSCT). Pediatr Blood Cancer 2011, 59:725-731.
11. Parsons S.K., Shih M.C., Duhamel K.N., et al. Maternal perspectives on children's health-related quality of life during the first year after pediatric hematopoietic stem cell transplant. JPediatr Psychol 2006, 31:1100-1115.
12. Bhatia M., Jin Z., Baker C., et al. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant 2014, 49:913-920.
13. Styczynski J., Tallamy B., Waxman I., et al. Apilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Bone Marrow Transplant 2011, 46:790-799.
14. Radhakrishnan K., Bhatia M., Geyer M.B., et al. Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease. Biol Blood Marrow Transplant 2013, 19:676-677.
15. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
16. Bearman S.I., Appelbaum F.R., Buckner C.D., et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. JClin Oncol 1988, 6:1562-1568.
17. Horn B., Soni S., Khan S., et al. Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies. Bone Marrow Transplant 2009, 43:469-476.
18. Varni J.W., Seid M., Kurtin P.S. PedsQLTM 4.0: Reliability and validity of the Pediatric Quality of Life Inventory TM Version 4.0 Generic Core Scales in healthy and patient populations. Med Care 2001, 39:800-812.
19. Varni J.W., Burwinkle T.M., Seid M., Skarr D. The PedsQLTM 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pedatr 2003, 3:329-341.
20. Brice L., Wei Y., Satwani P., et al. Quality of life including pretreatment variables and outcome for pediatric recipients of hematopoietic stem cell transplantation. Pediatr Blood Cancer 2011, 57:1179-1185.
21. Kupst M.J., Penati B., Debban B., et al. Cognitive and psychosocial functioning of pediatric hemopoietic stem cell transplant patients: A prospective longitudinal study. Bone Marrow Transplant 2002, 30:609-617.
22. Arnold S., Zhezhen J., Bishop J., et al. Allogeneic stem cell transplantation for children with sickle cell disease reduces healthcare utilization [abstract]. Biol Blood Marrow Transplant 2013, 19:S241-S242.
23. Caocci G., Efficace F., Ciotti F., et al. Prospective assessment of health-related quality of life in pediatric patients with beta-thalassemia following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:861-866.
24. Parsons S.K., Phipps S., Sun L., et al. NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: health-related quality of life, functional, and neurocognitive outcomes. Biol Blood Marrow Transplant 2012, 18:162-171.
25. Shah A.J., Epport K., Azen C., et al. Progressive declines in neurocognitive function among survivors of hematopoietic stem cell transplantation for pediatric hematologic malignancies. JPediatr Hematol Oncol 2008, 30:411-418.
26. Oberg J.A., Bender J.G., Morris E., et al. Pediatric allo-SCT for malignant and non-malignant diseases: impact on health-related quality of life outcomes. Bone Marrow Transplant 2013, 48:787-793.
27. Robinson M.R., Daniel L.C., O'Hara E.A., et al. Insurance status as a sociodemographic risk factor for functional outcomes and health-related quality of life among youth with sickle cell disease. JPediatr Hematol Oncol 2014, 36:51-56.
28. Hovi L., Kurimo K., Taskinen M., et al. Suboptimal long-term physical performance in children and young adults after pediatric allo-SCT. Bone Marrow Transplant 2010, 45:738-745.
29. Bockenmeyer J., Chamboredon E., Missud F., et al. Development of psychological and intellectual performance in transplanted sickle cell disease patients: a prospective study from pretransplant period to 5 years after HSCT. Arch Pediatr 2013, 20:723-730.
30. Sickle Cell Disease: Data & Statistics. Centers for Disease Control andPrevention Website. Available at: Published September 16, 2011. Accessed: February 19,2014. http://www.cdc.gov/NCBDDD/sicklecell/data.html.
31. Panepinto J.A., Torres S., Bendo C.B., et al. PedsQL TM Sickle Cell Disease module: feasibility, reliability, and validity. Pediatr Blood Cancer 2013, 60:1338-1344.
32. Panepinto J.A., Torres S., Bendo C.B., et al. PedsQL TM Multidimensional Fatigue Scale in sickle cell disease: feasibility, reliability, and validity. Pediatr Blood Cancer 2014, 61:171-177.
33. Sheth S., Licursi M., Bhatia M. Sickle cell disease: time for a closer look at treatment options?. Br J Haematol 2013, 162:455-464.